Wakamoto Pharmaceutical Co.,Ltd.

Tokyo Stock Exchange 4512.T

Wakamoto Pharmaceutical Co.,Ltd. Price to Sales Ratio (P/S) on January 29, 2025: 0.95

Wakamoto Pharmaceutical Co.,Ltd. Price to Sales Ratio (P/S) is 0.95 on January 29, 2025, a 23.55% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Wakamoto Pharmaceutical Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 1.42 on September 24, 2024, which is 48.84% above the current Price to Sales Ratio (P/S).
Wakamoto Pharmaceutical Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 0.71 on March 05, 2024, which is -25.28% below the current Price to Sales Ratio (P/S).
Wakamoto Pharmaceutical Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.02.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4512.T

Wakamoto Pharmaceutical Co.,Ltd.

CEO	Mr. Arata Igarashi
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	2-2-2, Nihonbashi Honcho
Employees	403
Sector	Health Care
Industries Pharmaceuticals

Description

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years